<DOC>
	<DOCNO>NCT02110225</DOCNO>
	<brief_summary>The primary objective study assess safety tolerability two dose regimen recombinant human nerve growth factor ( rhNGF ) eye drop solution administer 6 month versus vehicle control patient typical retinitis pigmentosa . The secondary objective study attempt show dose response assess potential efficacy rhNGF dose regimen improve slow deterioration visual function outcomes 3 6 month . During 6 month follow-up period patient monitor determine evidence persistent biological effect discontinuation study treatment .</brief_summary>
	<brief_title>A Dose Ranging Study Evaluate Safety Potential Efficacy rhNGF Patients With Retinitis Pigmentosa ( RP )</brief_title>
	<detailed_description />
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Retinitis Pigmentosa</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Patients 18 year age old . Patients typical form RP characterize follow clinical feature : classic fundus appearance ( i.e . intraretinal pigment deposit , thin atrophy retinal pigment epithelium ( RPE ) mid far peripheral retina , relative RPE preservation macula , waxy pallor optic disc , attenuation retinal vessel ) , reduce delay ERG response , visual field constriction Best correct distance visual acuity ( BCDVA ) score ≥ 48 ETDRS letter ( equivalent 20/100 Snellen , +0.7 LogMar , 0.2 decimal fraction ) either eye time study enrollment . Documented evidence disease progression within 12 month prior enrollment study demonstrate ERG ( ≥20 % decrease b wave amplitude scotopic condition ≥25 % photopic condition ) and/or visual field test ( ≥10 % Goldman Visual Field express area square ≥3 dB decrease Humphrey Visual Field Mean Deviation ) . Only patient satisfy Informed Consent requirement may include study . The patient and/or his/her impartial witness must read , sign date Informed Consent document studyrelated procedure perform . The Informed Consent form sign patient and/or impartial witness must approve Ethics Committee ( IEC ) current study . Patients must ability willingness comply study procedure . Patients atypical , early onset ( first decade ) syndromic form RP ( e.g . paravenous , pericentral sector unilateral RP , Leber 's congenital amaurosis , Resfum disease , Usher syndrome , BardetBiedl syndrome , etc ) . Patients nonrecordable 30 Hz cone ERG either eye . Patients Goldman visual field le 20º use V4e target residual central visual field le 35 dB evaluate 242 program Humphrey visual field either eye . Evidence active ocular infection either eye . History uveitis evidence intraocular inflammation either eye . History evidence glaucoma intraocular pressure ( IOP ) great equal 21 mmHg either eye time study enrollment . Patients foveal thickness ≥ 250 micrometer ( evaluate OCT ) . History cystoid macular oedema presence cystoid macular oedema OCT time study enrolment . Anterior segment abnormality medium opacity obscure view posterior pole either eye . History ocular surgery ( include laser refractive surgical procedure ) either eye within 120 day study enrolment . Ocular surgery allow study treatment period elective ocular surgery procedure plan duration followup period . Treatment corticosteroid ( systemic , periocular intravitreal ) nonapproved , experimental , investigational neuroprotectant therapy ( systemic , topical , intravitreal ) either eye within 90 day study enrollment . Use medication study medication treatment ocular disease exception artificial tear study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Cone-Rod Degenerations</keyword>
	<keyword>Cone-Rod Dystrophy</keyword>
	<keyword>Cone-Rod Dystrophy 2</keyword>
	<keyword>Cone-Rod Retinal Dystrophy</keyword>
	<keyword>Pigmentary Retinopathy</keyword>
	<keyword>Retinal Cone-Rod Dystrophy</keyword>
	<keyword>Rod Cone Dystrophies</keyword>
	<keyword>Rod-Cone Dystrophy</keyword>
	<keyword>Tapetoretinal Degeneration</keyword>
</DOC>